Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease DOI Creative Commons
Jasmine Morales, Nico Gabriel, Loki Natarajan

и другие.

Alzheimer s & Dementia, Год журнала: 2024, Номер 20(8), С. 5236 - 5246

Опубликована: Июнь 21, 2024

Abstract INTRODUCTION Bumetanide, a loop diuretic, was identified as candidate drug for repurposing Alzheimer's disease (AD) based on its effects transcriptomic apolipoprotein E signatures. Cross‐sectional analyses of electronic health records suggest that bumetanide is associated with decreased prevalence AD; however, temporality between exposure and AD development has not been established. METHODS We evaluated Medicare claims data using Cox proportional hazards regression to evaluate the association time‐dependent use time first diagnosis while controlling patient characteristics. Multiple sensitivity were conducted test robustness findings. RESULTS sampled 833,561 beneficiaries, 60.8% female, mean (standard deviation) age 70.4 (12). Bumetanide significantly risk (hazard ratio 1.05; 95% confidence interval, 0.99–1.10). DISCUSSION Using nationwide dataset retrospective cohort study design, we able identify effect lowering risk. Highlights (AD). AD. used accounted duration use.

Язык: Английский

Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease DOI Creative Commons
Jasmine Morales, Nico Gabriel, Loki Natarajan

и другие.

Alzheimer s & Dementia, Год журнала: 2024, Номер 20(8), С. 5236 - 5246

Опубликована: Июнь 21, 2024

Abstract INTRODUCTION Bumetanide, a loop diuretic, was identified as candidate drug for repurposing Alzheimer's disease (AD) based on its effects transcriptomic apolipoprotein E signatures. Cross‐sectional analyses of electronic health records suggest that bumetanide is associated with decreased prevalence AD; however, temporality between exposure and AD development has not been established. METHODS We evaluated Medicare claims data using Cox proportional hazards regression to evaluate the association time‐dependent use time first diagnosis while controlling patient characteristics. Multiple sensitivity were conducted test robustness findings. RESULTS sampled 833,561 beneficiaries, 60.8% female, mean (standard deviation) age 70.4 (12). Bumetanide significantly risk (hazard ratio 1.05; 95% confidence interval, 0.99–1.10). DISCUSSION Using nationwide dataset retrospective cohort study design, we able identify effect lowering risk. Highlights (AD). AD. used accounted duration use.

Язык: Английский

Процитировано

1